M. C. C.
- Country
- Spain
- Department
- Hematology
Research Overview
- HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
- HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Data & Insights
Has run more than one trial at 104 of 168 partner sites.
Specializations
Hematologic Malignancies
The investigator concentrates on acute myeloid leukemia (AML) and associated myelodysplastic syndrome subtypes, including high‑risk and measurable residual disease settings.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Multiple myeloma
- Newly diagnosed AML with NPM1 mutation
- FLT3‑mutated AML
- IDH1/IDH2‑mutated AML
Therapeutic strategies explored encompass targeted inhibitors, immunotherapy, and transplantation approaches.
Cardiovascular & Thrombotic Disorders
Research activity addresses atherosclerotic cardiovascular disease, acute coronary syndrome, and heart failure with reduced ejection fraction.
- Atherosclerotic cardiovascular disease
- Acute coronary syndrome
- Myocardial infarction
- Heart failure with reduced ejection fraction
- Major adverse cardiovascular events
- Hypertension
Efforts aim to reduce ischemic events through anti‑inflammatory and antithrombotic agents.
Respiratory & Critical Care
The investigator engages in studies of severe community‑acquired bacterial pneumonia and acute respiratory distress syndrome related to infectious etiologies.
- Severe community‑acquired bacterial pneumonia
- Ventilator‑associated pneumonia
- Acute respiratory distress syndrome
- Hospital‑acquired bacterial pneumonia
Investigations evaluate novel antimicrobial combinations and host‑directed therapies.
Metabolic & Liver Diseases
Interest includes metabolic disorders such as metabolic associated fatty liver disease with prediabetes and severe hypertriglyceridemia.
- Metabolic associated fatty liver disease
- Severe hypertriglyceridemia
- Prediabetes
- Lipid‑modifying therapies
Therapeutic focus is on agents that modify lipid metabolism and improve hepatic outcomes.
Immunology & Allergic Disorders
The investigator also studies immune‑mediated conditions like allergic rhinoconjunctivitis and immunoglobulin A nephropathy.
- Allergic rhinoconjunctivitis
- Immunoglobulin A nephropathy
- Allergen immunotherapy
- Cytokine inhibition
Approaches target cytokine pathways and allergen desensitization.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.